Hi-Tech Pharmacal Receives Final Approval for Dorzolamide Ophthalmic Solution
Posted on: Thursday, 30 October 2008, 03:00 CDT
Hi-Tech Pharmacal, a specialty pharmaceutical company, has announced that the FDA granted final approval to the company's abbreviated new drug application for dorzolamide ophthalmic solution, 2%.
Hi-Tech's dorzolamide ophthalmic solution is the generic for Merck's Trusopt ophthalmic solution 2%, indicated for elevated intraocular pressure in patients with ocular hypertension or open-angel glaucoma.
Hi-Tech said that it plans to launch generic dorzolamide ophthalmic solution 2% immediately.
Source: Datamonitor
Related Articles
- Hi-Tech Pharmacal Files Suit to Confirm the Company's Market Exclusivity Status Regarding Dorzolamide and Timolol Ophthalmic Solution
- FDC Wins Approval for Ciprofloxacin Ophthalmic Solution
- FDA Approves Akorn's Ofloxacin Ophthalmic Solution
- FDA Grants Tentative Approval for Hi-Tech's Generic Ophthalmic Solution
- Hi-Tech Pharmacal Receives Tentative Approval for Dorzolamide Hydrochloride With Timolol Maleate Ophthalmic Solution
- Allergan, Inc. Receives FDA Approval for COMBIGAN(TM) (Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution) 0.2%/0.5%
- Alcon's Eye Allergy Drug, PATANOL(R) Ophthalmic Solution, Approved in Japan
- Mast Cell Stabilization and Anti-Histamine Effects of Olopatadine Ophthalmic Solution: a Review of Pre-Clinical and Clinical Research
- Comparative Efficacy of Olopatadine 0.1% Ophthalmic Solution Versus Levocabastine 0.05% Ophthalmic Suspension Using the Conjunctival Allergen Challenge Model
Rating: 3.4 / 5 (10 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds